The pathway-selective estrogen receptor ligand WAY-169916 displays differential activity in ischemia-reperfusion injury models

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 6, 2006, Pages 788-795

  Harnish, Douglas C ^a   Liu, Xiaorong ^a   Kenney, Thomas ^a   Winneker, Richard C ^a   Chadwick, Chris ^a,b   Friedrichs, Gregory S ^a,c   Kilbourne, Edward J ^a  

^a PFIZER INC   (United States)

^b Life Diagnostics Inc   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Estrogen; Estrogen receptor; Heart; Ischemia; Reperfusion

Indexed keywords

CREATINE KINASE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG; WAY 169916;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; ENZYME RELEASE; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART PROTECTION; LEFT CORONARY ARTERY; MALE; NONHUMAN; PERFUSION PRESSURE; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; TREATMENT OUTCOME; UTERUS WEIGHT;

ANIMALS; CARDIOTONIC AGENTS; CHOLESTEROL; DISEASE MODELS, ANIMAL; ESTRADIOL; FEMALE; LIGANDS; MALE; MYOCARDIAL REPERFUSION INJURY; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; UTERUS;

EID: 33748111474     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000211793.60528.f7     Document Type: Article

References (56)

1. Karas RH, Hodgin JB, Kwoun M, et al. Estrogen inhibits the vascular injury response in estrogen receptor β-deficient female mice. Proc Natl Acad Sci USA. 1999;96:15133-15136.
2. Bhavnani BR, Cecutti A, Gerulath A, et al. Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women. Menopause. 2001;8:408-419.
3. Koh KK, Mincemoyer R, Bui M, et al. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med. 1997;336:683-690.
4. Herrington DM, Espeland MA, Crouse JR, et al. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Atheroscler Thromb Vasc Biol. 2001;21:1955-1961.
5. Hale SL, Birnbaum Y, Kloner RA. β-estradiol, but not α-estradiol, reduces myocardial necrosis in rabbits after ischemia and reperfusion. Am. Heart J. 1996;132:258-262.
6. Delyani JA, Murohara T, Nossuli TO, et al. Protection from myocardial reperfusion injury by acute administration of 17β-estradiol. J Mol Cell Cardiol. 1996;28:1001-1008.
7. Nabulsi A, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328:1069-1075.
8. Gebara O, Mittleman M, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the framingham offspring study. Circulation. 1995;91:1952-1958.
9. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post menopausal women. JAMA. 1998;280:605-613.
10. Women's Health Initiative Writing Group. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288:321-333.
11. Cushman M, Kuller L, Prentice P, et al. for the Women's Health Initiative Investigators, Estrogen Plus Progestin and Risk of Venous Thrombosis. JAMA. 2004;292:1573-1580.
12. Kuiper G, Carlsson B, Grandian K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptor alpha and beta. Endocrinology. 1997;138:863-870.
13. Grohe C, Kahlert S, Lobbert K, et al. Expression of oestrogen receptor alpha and beta in rat heart: role of local oestrogen synthesis. J Endocrinol. 1998;156:R1-R7.
14. Shughrue PJ, Merchenthaler I. Estrogen prevents the loss of CA1 hippocampal neurons in gerbils after ischemic injury. Neuroscience. 2003;116:851-861.
15. Tornwall J, Carey AB, Fox RI, et al. Estrogen in autoimmunity: expression of estrogen receptors in thymic and autoimmune T cells. J Gender-Specific Med. 1999;2:33-40.
16. Cowley SM, Hoare S, Mosselman S, et al. Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem. 1997;272:19858-19862.
17. Pace P, Taylor J, Suntharalingam S, et al. Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J Biol Chem. 1997;272:25832-25838.
18. Valentine JE, Kalkhoven E, White R, et al. Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression. J Biol Chem. 2000;275:25322-25329.
19. Tyree CM, Zou A, Allegretto EA. 17beta-Estradiol inhibits cytokine induction of the human E-selectin promoter. J Steroid Biochem Mol Biol. 2002;80:291-297.
20. Kilbourne EJ, Scicchitano MS. The activation of plasminogen activator inhibitor-1 expression by IL-1β is attenuated by estrogen in hepatoblastoma HepG2 cells expressing estrogen receptor α. Thromb Haemost. 1999;81:423-427.
21. Mukherjee TK, Nathan L, Dinh H, et al. 17-Epiestriol, an estrogen metabolite, is more potent than estradiol in inhibiting vascular cell adhesion molecule 1 (VCAM-1) mRNA expression. J Biol Chem. 2003;278:11746-11752.
22. Caulin-Glaser T, Watson CA, Pardi R, et al. Effects of 17-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest. 1996;98:36-42.
23. Evans MJ, Lai K, Shaw LJ, et al. Estrogen receptor alpha inhibits IL-1beta induction of gene expression in the mouse liver. Endocrinology. 2002;143:2559-2570.
24. Cuzzocrea S, Mazzon E, Sautebin L, et al. The protective role of endogenous estrogens in carrageenan-induced lung injury in the rat. Mol Med. 2001;7:478-487.
25. Miyamoto N, Mandai M, Suzuma I, et al. Estrogen protects against cellular infiltration by reducing the expressions of E-selectin and IL-6 in endotoxin-induced uveitis. J Immunol. 1999;163:374-379.
26. Harnish DC, Albert LM, Leathurby Y, et al. Beneficial effects of estrogen treatment in the HLA-B27 transgenic rat model of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2004;286:118-125.
27. Stein B, Yang MX. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol. 1995;15:4971-4979.
28. Ray A, Prefontaine KE, Ray P. Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J Biol Chem. 1994;269:12940-12946.
29. Ray P, Ghosh SK, Zhang DH, et al. Repression of interleukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. FEBS Lett. 1997;409:79-85.
30. Deshpande RH, Khalili RG, Pergolizzi SD, et al. Estradiol downregulates LPS-induced cytokine production and NF-kB activation in murine macrophages. Am J Repro Immunol (Copenhagen). 1997;38:46-54.
31. Sun WH, Keller ET, Stebler BS, et al. Estrogen inhibits phorbol ester-induced I kappa B alpha transcription and protein degradation. Biochem Biophys Res Comm. 1998;244:691-695.
32. Speir EZ, Yu X, Takeda K, et al. Competition for p300 regulates transcription by estrogen receptors and nuclear factor-kappa B in human coronary smooth muscle cells. Circ Res. 2000;87:1006-1011.
33. Harnish DC, Scicchitano MS, Adelman SJ, et al. The role of CBP in estrogen receptor cross-talk with nuclear factor-kappaB in HepG2 cells. Endocrinology. 2000;141:3403-3411.
34. Squadrito F, Deodato B, Squadrito G, et al. Gene transfer of IB limits infarct size in a mouse model of myocardial ischemia-reperfusion injury. Lab Invest. 2003;83:1097-1104.
35. Squadrito F, Altavilla D, Squadrito G, et al. 17â-Oestradiol reduces cardiac leukocyte accumulation in myocardial ischaemia reperfusion injury in rat. Eur J Pharm. 1997;335:185-192.
36. Wen Y, Yang S, Liu R, et al. Estrogen attenuates nuclear factor-kappa B activation induced by transient cerebral ischemia. Brain Res. 2004;1008:147-154.
37. Booth EA, Marchesi M, Kilbourne EJ, et al. 17β-Estradiol as a receptor-mediated cardioprotective agent. J Pharmacol Exp Ther. 2003;307:395-401.
38. Chadwick CC, Chippari S, Matelan E, et al. Identification of pathway-selective estrogen receptor ligands that inhibit NF-κB transcriptional activity. PNAS. 2005;102:2543-2548.
39. Keith JC, Albert LM, Leathurby Y, et al. The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-ěB transcriptional activity in models of rheumatoid arthritis. Arthritis Res Ther. 2005;7:R427-R438.
40. Lundeen SG, Carver JM, McKean M, et al. Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels. Endocrinology. 1997;138:1552-1558.
41. Li HY, Bian JS, Kwan YW, et al. Enhanced responses to 17β-estradiol in hearts treated with isoproterenol: involvement of a cyclic AMP-dependent pathway. J Pharmacol Exp Ther. 2000;293:592-598.
42. Lee TM, Su SF, Tsai CC, et al. Cardioprotective effects of 17β-estradiol produced by activation of mitochondrial ATP-sensitive K+ channels in canine hearts. J Mol Cell Cardiol. 2000;32:1147-1158.
43. Booth EA, Obeid NR, Lucchesi BR. Activation of estrogen receptor alpha protects the in vivo rabbit heart from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2005;289:H2039-H2047.
44. Zhai P, Eurell TE, Cooke PS, et al. Myocardial ischemia-reperfusion injury in estrogen receptor-α knockout and wild-type mice. Am J Physiol Heart Circ Physiol. 2000;278:H1640-H1647.
45. Merchenthaler I, Dellovade T, Shughrue PJ. Neuroprotection by estrogen in animal models of global and focal ischemia. Ann NY Acad Sci. 2003;1007:89-100.
46. Kovanen PT, Brown MS, Goldstein JL. Increased binding of low density lipoprotein to liver membranes from rats treated with 17 alpha-ethinyl estradiol. J Biol Chem. 1979;254:11367-11373.
47. Srivastava R, Baumann D, Schonfeld G. In vivo regulation of low-density lipoprotein receptors by estrogen differs at the post-transcriptional level in rat and mouse. Eur J Biochem. 1993;216:527-538.
48. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 1994;93:63-69.
49. Nekooeian AA, Pang CC. Effects of estrogen on venous function in rats with chronic heart failure. Am J Physiol Heart Circ Physiol. 2000;278:1941-1947.
50. Kolodgie FD, Farb A, Litovsky SH, et al. Myocardial protection of contractile function after global ischemia by physiologic estrogen replacement in the ovariectomized rat. J Mol Cell Cardiol. 1997;29:2403-2414.
51. 2+- independent nitric oxide synthase by 17β-estradiol in post-ischemic rat heart. Cardiovasc Res. 2000;46:111-118.
52. Simoncini T, Hafezi-Moghadam A, Brazil DP, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000;407:538-541.
53. Haynes MP, Sinha D, Russell KS, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res. 2000;87:677-682.
54. 2+-activated K+ channels in coronary vasodilation induced by 17β-estradiol in ischemic heart failure. FASEB J. 1997;11:793-799.
55. Bracamonte MP, Miller VM. Vascular effects of estrogens: arterial protection verses venous thrombotic risk. Trends Endocrinol Metab. 2001;12:204-209.
56. Cano A, Van Baal WM. The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas. 2001;40:17-38.